A PHASE 3, DOUBLE-BLIND RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF RITUXIMAB PLUS LENALIDOMIDE (CC-5013) VERSUS RITUXIMAB PLUS PLACEBO IN SUBJECTS WITH RELAPSED/REFRACTORY INDOLENT LYMPHOMA
The goal of this research study is to learn if adding Revlimid® (lenalidomide) to rituximab can help to control FL and/or MZL. The safety of this drug combination will also be studied.
Treatment Location: N/A
IRB Review and Approval Date: 07/30/2015
Recruitment Status: Closed
Projected Accrual: N/A
Information and next steps
For general questions about clinical trials: